Betalin Therapeutics Ltd.

Betalin Therapeutics Ltd. is dedicated to developing innovative diabetes management solutions through the engineered micro-pancreas, an advanced medical device that autonomously regulates insulin production using stem cell technology. Established in 2015, Betalin Therapeutics Ltd. is based in Ramat Gan, Israel.

The company focuses on creating solutions for diabetes care and has secured EUR 500,000 in funding from the European Innovation Council. The co-founders, Shay Hershcovici and Shuki Hershcovich, have backgrounds in engineering and medical technology. The latest funding round occurred on January 26, 2022, marking the third deal for the company, with a total amount raised of EUR 500,000. Betalin Therapeutics specializes in developing an innovative solution for diabetes management through its flagship product, the engineered micro-pancreas (EMP).

This advanced medical device employs state-of-the-art stem cell technology and tissue engineering to create a functional micro-pancreas that can autonomously regulate insulin production in response to a patient’s glucose levels. The EMP is integrated into a supportive micro-organ matrix (MOM) that mimics the natural extracellular environment of pancreatic beta cells, enhancing their survival and functionality. This solution targets the estimated 500 million individuals globally living with diabetes, addressing the limitations of current insulin replacement therapies. The micro-pancreas is designed for outpatient use and can be implanted subcutaneously in various geographical markets, including Europe, North America, and select regions in Asia, providing a more stable and effective alternative to traditional insulin therapies.

Betalin Therapeutics generates revenue through partnerships and collaborations with healthcare institutions and potentially direct sales to clinics that offer innovative diabetes treatments. The company structures transactions around the distribution of its engineered micro-pancreas, establishing agreements for exclusive distribution rights or licensing arrangements with medical device manufacturers. Revenue is anticipated from the sale of micro-pancreas systems, with streamlined implantation processes reducing associated healthcare costs. The pricing model reflects the advanced technology and support services provided, positioning the EMP as a premium product in the diabetes management sector.

While specific pricing details are not disclosed, the market entry strategy suggests a focus on establishing a robust client base among healthcare providers and diabetes treatment centers. In January 2022, Betalin Therapeutics Ltd. raised EUR 500,000 in venture funding from the European Innovation Council. The funding will be utilized to conduct human trials of a biological pancreas and advance its therapy for diabetes treatment.

As part of its future growth strategy, the company plans to design and launch new products aimed at enhancing diabetes management and aims to expand its reach into new markets, focusing on Europe, North America, and specific regions in Asia by 2025.